Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 305

Results For "IMI"

3571 News Found

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Moderna and Carisma Therapeutics partner to develop CAR-M therapeutics
Biotech | January 10, 2022

Moderna and Carisma Therapeutics partner to develop CAR-M therapeutics

Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note


Moderna Covid-19 boosters after five-month interval: U.S. FDA
News | January 08, 2022

Moderna Covid-19 boosters after five-month interval: U.S. FDA

Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older


Exscientia and Sanofi collaborate for AI-driven precision-engineered medicine
Biotech | January 08, 2022

Exscientia and Sanofi collaborate for AI-driven precision-engineered medicine

Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties


Lilly and Entos  collaborate for therapies in multiple neurologic indications
Biotech | January 07, 2022

Lilly and Entos collaborate for therapies in multiple neurologic indications

Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly


Jubiant Therapeutics gets USFDA clearance for JBI-802 to treat solid tumours
Biotech | January 07, 2022

Jubiant Therapeutics gets USFDA clearance for JBI-802 to treat solid tumours

JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6


Margins under pressure; domestic market growth to slow down: Nirmal Bang
News | January 06, 2022

Margins under pressure; domestic market growth to slow down: Nirmal Bang

A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies


Biotium introduces unique super-sensitive RNA Prestain Loading Dye
Biotech | January 06, 2022

Biotium introduces unique super-sensitive RNA Prestain Loading Dye

EMBER500RNA Prestain Loading Dye allows single-step denaturing, loading, and bright RNA staining on regular agarose gels


NATHEALTH Home Care Forum launches white paper on healthcare delivery
Healthcare | January 06, 2022

NATHEALTH Home Care Forum launches white paper on healthcare delivery

10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies


ENTOD Pharmaceuticals set to launch Molentod
News | January 06, 2022

ENTOD Pharmaceuticals set to launch Molentod

It is the generic version of molnupiravir